on OXURION (EBR:OXUR)
Oxurion Receives Transparency Update from Atlas Special Opportunities LLC
Oxurion NV, a biopharmaceutical player based in Leuven, Belgium, has informed of the receipt of an adjusted transparency notification in accordance with Belgian law. This notification, dated January 13, 2025, comes from Atlas Special Opportunities LLC. It reveals that as of January 30, 2024, Atlas held 35,039 shares out of a total of 3,192,223 outstanding shares of Oxurion, thus falling below the 3% threshold through the sale of voting securities.
This press release corrects the one published on January 3, 2025. Oxurion continues to focus on the development of novel ophthalmic therapies for retinal diseases. For more information, visit the company's website.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news